Summit Therapeutics Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Summit Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $3.67M.
- Summit Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-12-31 was $1.22M, a 104.70% increase year-over-year.
- Summit Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $730.00K.
- Summit Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $241.00K.
- Summit Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $3.09M, a 415.53% increase from fiscal 2020.
- Summit Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $599.00K.
- Summit Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $133.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $3.67M 10-Q · filed 2026-07-23 | |
| 2021-12-31 | $1.22M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $3.09M 10-K/A · filed 2022-12-21 |
| 2021-09-30 | $730.00K 10-Q · filed 2022-11-09 | $2.46M derived: sum of 4 quarters · filed 2022-12-21 |
| 2021-06-30 | $241.00K 10-Q · filed 2022-08-11 | $1.73M derived: sum of 4 quarters · filed 2022-12-21 |
| 2021-03-31 | $897.00K 10-Q · filed 2022-05-11 | $1.49M derived: sum of 4 quarters · filed 2022-12-21 |
| 2020-12-31 | $596.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $599.00K 10-K/A · filed 2022-12-21 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2020-03-31 | $3.00K 10-Q · filed 2021-05-17 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | |
| 2019-06-30 | $2.00K 8-K · filed 2020-09-29 | |
| 2019-01-31 | $133.00K 10-K · filed 2021-03-31 | |
| 2018-01-31 | $521.00K 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |